scholarly journals The global procurement landscape of leishmaniasis medicines

2021 ◽  
Vol 15 (2) ◽  
pp. e0009181
Author(s):  
Hye Lynn Choi ◽  
Saurabh Jain ◽  
José A. Ruiz Postigo ◽  
Bettina Borisch ◽  
Daniel Argaw Dagne
Keyword(s):  
Supply And Demand ◽  
Coordination Mechanism ◽  
Essential Medicines ◽  
National Programmes ◽  
Global Demand ◽  
Control Programmes ◽  
Access To Essential Medicines ◽  
Supply Planning ◽  
Treat All ◽  
A Current

Ensuring access to essential medicines for leishmaniasis control is challenging, as leishmaniasis is a very small and unattractive market for pharmaceutical industry. Furthermore, control programmes are severely underfunded. We conducted an analysis of global procurement of leishmaniasis medicines for the past 5 years in order to shed light on the current leishmaniasis market landscape and supply and demand dynamics. We estimated global demand of each leishmaniasis medicines, the amount of each medicine required to treat all reported cases, based on the number of cases reported to WHO and the first-line treatment regimen used in each country. Procurement data were obtained from procurement agencies, international organizations, WHO, national leishmaniasis programmes and manufacturers. Expert interviews were conducted to have a better understanding of how medicines were procured and used. The comparison of estimated need and procurement data indicated discrepancies in supply and demand at global level as well as in the most endemic countries. The extent of the gap in supply was up to 80% of the needs for one of the leishmaniasis medicines. Mismatch between supply and demand was much wider for cutaneous leishmaniasis than visceral leishmaniasis. This study presents a current picture of procurement patterns and imbalance in global supply and demand. Addressing improved access and supply barriers requires concerted and coordinated efforts at the global and national levels. Priority actions include setting up a procurement coordination mechanism among major procurers, partners and national programmes where forecasting and supply planning is jointly developed and communicated with manufacturers. In addition, continuous engagement of manufacturers and advocacy is critical to diversify the supplier base and ensure quality-assured and affordable generic medicines for leishmaniasis.

Reports on Recent Activities of European Food Safety Authority

2019 ◽  
Vol 30 (5) ◽  
pp. 217-220
Keyword(s):  
Pesticide Residues ◽  
Food Products ◽  
Sampling Procedure ◽  
Control Programme ◽  
The European Union ◽  
Eu Member States ◽  
Official Control ◽  
National Programmes ◽  
Control Programmes ◽  
Risk Managers

This report provides an overview of the 2017 official control activities on pesticide residues carried out in the European Union (EU) Member States, Iceland and Norway. It summarises the results of both the 2017 EU-coordinated control programme (EUCP) and the national control programmes (NP). While the NPs are mostly risk based (so called enforcement samples) focusing on pesticides or products originating from countries where a number of exceedances have been observed in the past, the EUCP aims to present a statistically representative snapshot of the situation of pesticide residues in food products that are mostly consumed in the EU following a random sampling procedure. The report includes the outcome of a dietary risk assessment based on the results of the overall 2017 control programmes. The comprehensive analysis of the results of all reporting countries provides risk managers with sound-based evidence for designing future monitoring programmes, in particular for taking decisions on which pesticides and food products should be targeted in risk-based national programmes.

scholarly journals The Pandemic, Patient Advocacy, and the Importance of Thinking Comment on "The Rise of the Consucrat"

2020 ◽  
Author(s):  
Órla O’Donovan
Keyword(s):  
Pharmaceutical Industry ◽  
Patient Advocacy ◽  
Essential Medicines ◽  
Human Patient ◽  
Patient Advocates ◽  
Access To Essential Medicines ◽  
Global Access ◽  
Ways Of Thinking

The profound inadequacies of Western modernist ways of thinking have been revealed by the intimately connected catastrophes of climate destruction, and more recently, the coronavirus crisis. The pandemic has forced us to notice deepening inequalities and has generated troubling questions about its causes, and who and what can be sacrificed in a pandemic. The analysis offered in Evelyn de Leeuw’s essay "The rise of the consucrat" suggests that the particular type of patient advocates she calls consucrats are unlikely to engage in thinking together about these urgent questions. If anything, due to their narrow biomedical focus and alliances with the pharmaceutical industry, they are likely to facilitate catastrophe capitalism. However, within the field of patient advocacy, there is a diversity of ways of thinking, occasionally leading to bitter contention. A number of terms is needed to reflect this diversity. One group of patient advocates who have come to the fore in recent times might be called medical cosmopolitans, or cosmedics, those who are challenging opportunistic catastrophe capitalism during the pandemic and advocating for global access to essential medicines. Forcing us to notice our deep interdependencies and entanglements, the pandemic has revealed how ludicrous it is to think about patients as consumers, and the need to think about and imagine more-than-human patient advocacy.

Sign in / Sign up

Export Citation Format

Share Document